Tangri, Navdeep
Rastogi, Anjay
Nekeman-Nan, Cassandra http://orcid.org/0009-0002-9801-0110
Hong, Lai San
Ozaki, Asuka
Franzén, Stefan
Sofue, Tadashi
Funding for this research was provided by:
AstraZeneca
Article History
Received: 29 September 2023
Accepted: 14 December 2023
First Online: 19 January 2024
Declarations
:
: Cassandra Nekeman-Nan, Asuka Ozaki and Stefan Franzén are employees and shareholders of AstraZeneca. Cassandra Nan holds shares in GlaxoSmithKline. Navdeep Tangri has received grants from AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd and Tricida, Inc., has received honoraria from AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd and Tricida, Inc. and holds stock options from Mesentech, Inc., pulseData, Rénibus Therapeutics, Inc. and Tricida, Inc. Anjay Rastogi has received advisory board and speakers’ bureau fees from AstraZeneca and Relypsa Inc., has received research grants from AstraZeneca and Bayer, and has received consulting fees from Bayer. Lai San Hong was an independent contractor for AstraZeneca at the time that this study was conducted. Tadashi Sofue has received personal fees for lectures from AstraZeneca and Mitsubishi Tanabe Pharma.
: OPTIMISE-CKD used de-identified data from existing databases and did not require data collection beyond that of routine clinical care. No identifiable information was collected or examined as part of the study. All externally conducted analyses were completed in line with local ethics regulations/legislation. De-identified, internally licensed databases were shared with AstraZeneca by the licensee; therefore, ethics review and approval were not required for the use of these databases for this study.